PyInvesting

Market research

7148.KLSE CCM Duopharma Biotech Berhad

KLSE MYR Healthcare

Latest close

1.11 —

As of 30 Oct 2026

Test a moving-average rule with historical data.

Market facts
Market cap
1B
P/E ratio
9.82
Analyst target
1.686
Dividend yield
4.2%
Beta
0.36

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 6 months ago

CCM Duopharma Biotech Berhad is currently in a long term downtrend where the price is trading 12.9% below its 200 day moving average.

From a valuation standpoint, the stock is 45.5% cheaper than other stocks from the Other sector with a price to sales ratio of 3.5.

CCM Duopharma Biotech Berhad's total revenue sank by 6.4% to $134M since the same quarter in the previous year.

Its net income has dropped by 4.9% to $14M since the same quarter in the previous year.

Finally, its free cash flow grew by 503.0% to $6M since the same quarter in the previous year.

Based on the above factors, CCM Duopharma Biotech Berhad gets an overall score of 2/5.